Bristol-Myers Squibb Beat Estimates but Cut EPS Guidance in Q3 2026
Bristol-Myers Squibb reported Q3 2026 adjusted EPS of $1.35, exceeding estimates. The company reduced full-year EPS guidance due to $1.56B IPRD charges, despite higher revenue outlook. Eliquis sales grew 25%, while legacy drugs faced generic competition. The FDA approved Zenbexus, with a PDUFA date set for May 2027. The company has $5B in share repurchase authorization.
How this was made
The 30-second read
Why it matters
Traders should separate the earnings beat from the guidance cut mechanism: the $1.56B IPRD charges are the stated driver of lower non-GAAP EPS guidance, while revenue outlook moved higher and product momentum (Eliquis) remains a key offset.
Market read
This is a single-name earnings and guidance update with a clear accounting-charge explanation, plus product and regulatory catalysts that can influence near-term estimate revisions.
What to watch
Generic erosion is highlighted for legacy drugs (Revlimid and Pomalyst/Imnovid), which could cap durability of earnings despite Eliquis strength and the Zenbexus pipeline milestone.
Background
The piece frames BMY’s Q3 performance as a beat on adjusted EPS alongside a guidance reduction driven by acquired IPRD charges, while emphasizing Eliquis growth and a myeloma regulatory milestone (Zenbexus).
Ticker impact
Bristol-Myers Squibb reported Q3 adjusted EPS of $1.35, beat expectations, but trimmed full-year non-GAAP EPS guidance due to $1.56B IPRD charges.
Likely choppy trading, with initial downside from the guidance trim offset by relief from the EPS beat and improved revenue outlook.
The article provides a concrete earnings beat plus a specific, attributable guidance reduction ($1.56B IPRD charges), which typically drives near-term estimate revisions even when revenue trends improve.
Market effects
Biopharma investors may re-focus on how deal-related accounting charges (IPRD) can swing guidance, even when core product momentum remains strong.
Limited direct regional spillover implied; this is primarily a single-name earnings and guidance update.
Moderate global relevance via Eliquis growth and a new myeloma approval (Zenbexus) narrative, but the actionable catalyst is company-specific.
Counterpoint
The EPS guidance cut is explicitly attributed to one-time deal-related IPRD charges, so the market may look through it and focus on the higher revenue outlook and Eliquis growth.
Key entities
- companyBristol-Myers Squibb
Reported Q3 adjusted EPS beat, trimmed full-year non-GAAP EPS guidance due to $1.56B IPRD charges, and highlighted Zenbexus FDA approval and Eliquis growth.
- productEliquis
Reported 25% worldwide growth, with strong U.S. demand cited as a driver.
- productZenbexus
First-in-class CELMoD for multiple myeloma; FDA approval highlighted, with Phase 3 PFS data and a mezigdomide PDUFA date set for May 13, 2027.
- productRevlimid
Legacy drug facing generic competition, cited as being carved up by generics.
- productPomalyst/Imnovid
Legacy drugs facing generic competition, cited as being carved up by generics.
